Evidence map›Paper›PMID 33830822›Full record

ArticleJCO oncology practice2021

Understanding Active Surveillance for Prostate Cancer.

Lillian Y Lai, Vahakn B Shahinian, Mary K Oerline, Samuel R Kaufman, Ted A Skolarus, Megan E V Caram, Brent K Hollenbeck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Lillian Y LaiDepartment of Urology, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-0831-2979
Vahakn B ShahinianDepartment of Urology, University of Michigan, Ann Arbor, MI.
Mary K OerlineDepartment of Urology, University of Michigan, Ann Arbor, MI.
Samuel R KaufmanDepartment of Urology, University of Michigan, Ann Arbor, MI.
Ted A SkolarusDepartment of Urology, University of Michigan, Ann Arbor, MI.
Megan E V CaramDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-1597-5428
Brent K HollenbeckDepartment of Urology, University of Michigan, Ann Arbor, MI.

Funding

De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spendingR01HS025707 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2017 to 2021
$1.7M
Refining castration use for recurrent prostate cancerR01CA242559 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SKOLARUS, TED ALBERT, TSODIKOV, ALEXANDER · 2020 to 2023
$1.4M
AHRQ HHS R01 HS025707NCI NIH HHS R01 CA242559NCI NIH HHS R37 CA222885NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

purposeTo assess how active surveillance for prostate cancer is apportioned across specialties and how testing patterns and transition to treatment vary by specialty.

methodsWe used a 20% national sample of Medicare claims to identify men diagnosed with prostate cancer from 2010 through 2016 initiating surveillance (N = 13,048). Patients were assigned to the physician responsible for the bulk of surveillance care based on billing patterns. Freedom from treatment was assessed by specialty of the responsible physician (urology, radiation oncology, medical oncology, and primary care). Multinomial logistic regression models were used to examine associations between specialty and treatment patterns.

resultsUrologists were responsible for surveillance in 93.7% of patients in 2010 and 96.2% of patients in 2016 (

conclusionNontrivial percentages of patients on active surveillance are managed by physicians outside of urology. Given the interspecialty variations observed, efforts to strengthen the evidence underlying surveillance pathways and to engage other specialties in guideline development are needed.

Indexed as

Prostatic NeoplasmsWatchful WaitingAgedHumansMaleMedicarePractice Patterns, Physicians'ProstatectomyUnited States

Identifiers

PMID33830822
PMCPMC9810129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.